MSX Opens Pre-IPO Phase 3 for Neuralink and Anduril

This signals growing retail or accredited investor demand for late-stage private tech exposure, a space historically reserved for venture funds and insiders. The significance lies in the platform's ability to aggregate allocations in marquee names like Neuralink and Anduril, which could democratize access but also concentrate risk in illiquid, high-valuation assets. The key watchpoint is whether this phase attracts enough uptake to validate the platform's model, and how secondary-market liquidity for such shares develops after listing. For market observers, the real test is whether this trend reshapes how private capital flows reach frontier-tech companies.